NovoMab BioPharmaceuticals Inc CTLA-4 Antibody Patent US12606624B2

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

The USPTO granted Patent US12606624B2 to NovoMab BioPharmaceuticals Inc covering an antibody that specifically binds to human CTLA-4. The patent discloses three complementarity-determining regions (CDR1-3) and applications in medicaments and kits for potential tumor growth inhibition. The patent application (18456503) was filed on August 27, 2023.